A series of ULK1 inhibitors have demonstrated antitumor effects in vitro and in xenograft models29,30, and selective ULK1 inhibitors have shown synergistic tumor regression when combined with KRas or downstream effector inhibitors31. Here, ULK1 is linked to neoplasm.